The RET/PTC inhibitor LOXO292 (selpercatinib) has been approved by the US Food and Drug Administration to treat RET-altered cancers, including advanced thyroid cancer harboring RET/PTC, with good therapeutic responses in some patients but not in others (43). The gene discussed is CCDC6; the disease is thyroid gland carcinoma.